PM360, June 2012
As therapies get more nuanced and complex, they are more difficult to size. Anonymized, longitudinal, patient-level data can allow for the most accurate estimate of market potential.
PM360, May 2012
The tried-and-true method for evaluating the importance of a physician has been to look at their historical prescribing patterns. Today, manufacturers can leverage anonymized, patient-level data to further refine their prescriber evaluation methods.
PM360, March 2012
Where patients are initially prescribed a therapy, such as in a hospital, can impact patient behavior, and ultimately market share of a brand.
PM360, December 2011
To effectively reach and sell to physicians, facilities, and organizations, brand teams need an understanding of provider-provider relationships. Melissa Leonhauser explains how anonymous patient-level data provides previously unavailable insight into the informal links and relationships between providers.
PharmaVoice, February 2011
R&D directors in pharma and clinical research organizations can tap into secondary patient-level information to identify the most relevant patients for therapies and clinical trials.
AccessPoint, May 2011
Our latest HEOR newsletter features insights into U.S. healthcare reform, implications of AMNOG in Germany, the global convergence of HTAs, advances in adherence research, patient-reported outcomes and more.
Managed Healthcare Executive, March 2011
An assessment of clinical quality standards and their impact on cost, quality of care and outcomes.
Biotechnology Healthcare, Winter 2010/2011
The use of evidence-based medical research to support greater healthcare transparency.
Journal of Managed Care Pharmacy, November/December 2009
This study measures adherence and persistence across multiple drug classes, identifying substantial differences in therapy areas and suggesting important opportunities to improve the quality of drug therapy management.